Cleveland Clinic’s menopause service distinguishes medicines for hot flashes from nonhormonal products for vaginal dryness. That separation matters: a reader may want help with both, but the goals and the supporting evidence do not become the same simply because neither approach contains hormones.
Reviewed September 29, 2026, this assessment follows those separate subjects through the clinic’s care description and appointment information. It does not select a medicine or lubricant, promise symptom relief or establish a personal treatment plan. The published service is the evidence, with individual prescribing and purchase details still unresolved.
The service names more than one nonhormonal task
Cleveland’s menopause treatment page says its clinicians may recommend medicines to address hot flashes without hormones. It separately discusses over-the-counter lubricants for vaginal dryness. The service therefore presents nonhormonal care as more than one intervention directed at more than one concern.
Our visit-goals discussion helps keep that distinction visible before comparing treatment descriptions. The page does not identify a single medicine that covers both goals, and this review does not invent one. It also does not assume that every reader experiences the same symptoms. The initial comparison should concern what problem is being addressed, not which provider uses the broadest reassuring category.
A hot-flash medicine needs a name before its evidence can be assessed
The Cleveland page describes possible effects involving hot flashes, mood and sleep without naming the selected medication. Those statements are part of its clinical offer, not evidence that a specific person will experience all three changes. No particular drug family or product is assigned here beyond what the page establishes.
The medicine-family guide explains why a specific identity matters. Duke’s review examines a more explicit antidepressant-family description, while Cleveland’s wording remains broader. That information difference does not rank the quality of care. It identifies what a clinician would still need to explain before an individual medicine’s evidence, warnings and practical responsibilities could be considered.
A local comfort product does not inherit hot-flash evidence
Cleveland’s discussion of lubricants concerns vaginal dryness and comfort. It should not be interpreted as a claim about controlling hot flashes, protecting bone or treating every cause of pain. The product’s intended role is narrower than the full menu of concerns handled by a menopause service.
The 2023 Menopause Society abstract reviews nonhormonal approaches for vasomotor symptoms. That is a different evidence question from whether a local product helps a particular vaginal concern. Neither source supports borrowing outcomes between those goals. The clinician can assess the actual complaint and proposed approach; this review does not diagnose discomfort or recommend a specific product from the general category.
Sleep-support language should not be promoted into a universal remedy
The clinic page discusses herbal supplements and possible suggestions for sleep concerns. This does not establish that supplements have the same evidence as medicines for hot flashes. The 2023 professional abstract did not recommend supplements or herbal remedies as treatments for vasomotor symptoms.
That evidence boundary is about the stated outcome, not a claim that every discussion of sleep is illegitimate. The exact product and the reason it is being considered would still matter. Utah’s review examines another broad menu where general support and symptom-directed interventions need separate interpretation. No supplement protocol or assumption of safety is supplied by this article.
A shared visit and an individual medicine decision are different encounters
Cleveland’s appointment description includes group visits for information and questions. It specifies that medications or laboratory work require an individual follow-up with a menopause specialist. The shared session should therefore not be described as an immediate prescription pathway or a substitute for a private treatment assessment.
This distinction is useful for someone whose main uncertainty involves a medicine, its interactions or responsibility for follow-up. A group may provide context without resolving those individual questions. The service description does not promise that a particular drug will be prescribed after either format. Nor does it establish a personal laboratory plan simply because testing is mentioned as something that may require another encounter.
Clinical responsibility remains even when the chosen route avoids hormones
The FDA’s current overview recognizes several approved nonhormonal therapies. Their existence is not evidence that every option has the same precautions or is offered through each Cleveland location. A patient-specific proposal needs its own rationale and current product information.
The fezolinetant safety context is one example: the FDA describes serious liver-injury risk and testing responsibilities for that medicine. The monitoring guide discusses those responsibilities without choosing a personal schedule. Cleveland’s broad hot-flash medicine statement does not establish that it would select fezolinetant or that a nonhormonal approach avoids the need for professional monitoring.
Location and cost should follow the actual appointment being considered
The service page identifies menopause pathways in Ohio, Florida and London. Those locations are not one interchangeable access arrangement. A reader needs confirmation from the relevant practice rather than an assumption that a virtual or shared visit removes jurisdictional and individual conditions.
The page describes the shared-appointment cost in relation to a regular visit, but it does not provide a complete personal quote for further assessment and medication. The eventual pharmacy purchase remains another question. This review confirms a real service with distinct nonhormonal subjects and appointment formats. It does not verify a bill, insurance payment, selected product or treatment result, and it does not combine separate symptom goals into one promised outcome.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Cleveland Clinic — Menopause TreatmentOfficial clinical service description, accessed September 29, 2026; an individual prescription, access arrangement, full price and outcome are not established. Published treatment categories are not an all-product formulary. · Checked 2026-09-29
- The 2023 nonhormone therapy position statement of The North American Menopause Society — PubMed abstractPrimary professional position-statement abstract, published 2023; vasomotor-symptom scope only. Full article not retrieved. Predates later drug approvals; does not evaluate these clinics or equate all forms of counseling. · Checked 2026-09-29
- FDA — Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsCurrent federal consumer overview, accessed September 29, 2026; confirms multiple approved nonhormonal therapies. Not a clinic’s formulary, a treatment protocol or proof all requested hormone-label changes are completed. · Checked 2026-09-29
- FDA — Fezolinetant serious liver-injury safety communicationFederal primary safety communication; the retrieved text displays the September 12, 2024 communication. Used for serious liver-risk and testing context only; current boxed warning and contraindications are separately supported by the current exact DailyMed label where discussed. · Checked 2026-09-29